Sarah Cannon Research Institute

The CELESTIAL-301 trial evaluating SynKIR-310, a novel CAR T-cell therapy, has dosed its first patient with relapsed/refractory B-cell non-Hodgkin lymphoma.

Recent regulatory activities suggest that the understanding of TROP2-directed therapies remains muddled.